Poor
Not Aligned
Patient Risk:
Moderate
Summary
The claims address nomenclature and general study context but do not align with (or are not supported by) the provided FDA label excerpt for KENGREAL. Critical labeling elements such as indication, dosing, contraindications, warnings, interactions, and population-specific information are not addressed.
Category Scores
Accurate Statements
Unsupported Statements
Cangrelor is being developed under the brand name cangrelor.
The provided label excerpts describe the marketed product as KENGREAL (active ingredient cangrelor) but do not state that cangrelor is being developed under the brand name 'cangrelor' rather than KENGREAL.
Cangrelor refers to the drug itself (a P2Y12 inhibitor).
The label excerpt states that 'Cangrelor is a direct P2Y12 platelet receptor inhibitor', but this claim is framed as 'Cangrelor refers to the drug itself' and does not clearly correspond to the label’s naming relationship (KENGREAL vs cangrelor). Without an explicit label statement equating cangrelor with the drug substance in that phrasing, it is treated as unsupported.
Cangrelor has been studied as an antiplatelet drug involving P2Y12 inhibition.
The label excerpt supports that cangrelor (KENGREAL) inhibits P2Y12 function and that the CHAMPION PHOENIX trial tests faster platelet inhibition at PCI; however, the claim is generic and not directly tied to the label’s specific study context/exact wording. Marked unsupported due to lack of explicit support for this generalized statement as written.
Cangrelor has been studied in settings such as acute coronary syndromes and related cardiovascular care.
The provided label excerpt does not mention 'acute coronary syndromes' explicitly. It describes PCI and periprocedural endpoints in CHAMPION PHOENIX but does not support the 'acute coronary syndromes' phrasing.
No widely established commercial brand name tied to a marketed product is specified in the provided information.
The provided FDA labeling excerpt clearly specifies the marketed product name: KENGREAL.
No widely recognized marketed brand equivalence is indicated in the provided information.
The label excerpt identifies the product name KENGREAL and active ingredient cangrelor. It does not address 'equivalence' language, but the claim that no marketed brand name is specified is contradicted by the presence of KENGREAL.
The specific marketed brand name is not specified in the provided information.
The label excerpt explicitly states 'KENGREAL is indicated...' and provides storage/NDC information for KENGREAL.
Contradictions
Low
AI Statement
No widely established commercial brand name tied to a marketed product is specified in the provided information.
Label Reference
Label excerpt shows marketed product name: 'KENGREAL is indicated...' and 'KENGREAL is supplied...' (Sections 1 and 16).
Low
AI Statement
The specific marketed brand name is not specified in the provided information.
Label Reference
Label excerpt shows marketed product name: 'KENGREAL is indicated...' and 'KENGREAL is supplied...' (Sections 1 and 16).
Important Omissions
FDA label core content is omitted, including the indicated use (adjunct to PCI to reduce periprocedural MI, repeat revascularization, and stent thrombosis), recommended dosing regimen (30 mcg/kg IV bolus then 4 mcg/kg/min infusion), contraindications (significant active bleeding; hypersensitivity), warnings/precautions (bleeding risk; no antiplatelet effect after discontinuation within 1 hour), and key interaction guidance (timing of thienopyridines after discontinuing KENGREAL).
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
The claims do not provide dosing, contraindications, or safety guidance; incorrect statements about product branding could contribute to confusion. No direct dose/safety misuse is stated, but omission of critical label safety elements is material.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Not Aligned
Primary Issue
Several claims misstate or contradict the label’s provided marketed product naming (KENGREAL) and make generalized study-context statements not explicitly supported by the excerpt.
Suggested Improvement
Restrict claims to label-supported facts from the provided excerpts (e.g., KENGREAL as the marketed product name; cangrelor as the active ingredient and direct P2Y12 receptor inhibitor; PCI/periprocedural endpoints in CHAMPION PHOENIX) and include label core elements when making drug-use claims (indication, dosing, contraindications, warnings, and key interactions).